Deborah Hall, MD
Neurology · Chicago, ILNPI 1952410334
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $13,979 of the $14,584 with a category attached, or 95.8%. Alnylam Pharmaceuticals Inc. accounts for 96.8% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2024 at $14,111 and has fallen 98.3% since, to $235 in 2025.
Across 12 payments — averaging $1215.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$14K
- Neurocrine Biosciences, Inc.$473
Across 243 payments — averaging $5503.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Neurocrine Biosciences, Inc.$305K
- H. Lundbeck A S$289K
- AbbVie$250K
- Sage Therapeutics, LLC$238K
- Regeneron$78K
- Biogen$73K
- plus $104K from 4 others
What the payments were for
- Travel & lodging$13,97996%
- Food & beverage$6054%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 8 | $14,111 |
| Neurocrine Biosciences, Inc. | 4 | $473 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,584 in reported general payments places this provider in the 85th percentile of 790 neurology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 37 | $277,116 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 434 | $13,867 |
| Entacapone | 58 | $11,747 |
| Carbidopa | 35 | $6,828 |
| Rasagiline Mesylate | 11 | $4,340 |
| AmantadineAmantadine Hcl | 101 | $3,693 |
| Rivastigmine | 28 | $3,071 |
| Propranolol Hcl ErPropranolol Hcl | 57 | $2,535 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 52 | $2,342 |
| Gabapentin | 150 | $2,155 |
| Donepezil Hcl | 102 | $1,336 |
| Midodrine Hcl | 12 | $1,071 |
| Primidone | 39 | $1,052 |
| Cyclobenzaprine Hcl | 12 | $756 |
| Memantine Hcl | 53 | $638 |
Paid to pharmacies, not to this prescriber.
Other neurology in Chicago
- Augusto MiravalleChicago$1.4M
- Adil JavedChicago$584K
- Danny BegaChicago$442K
- Michael SmithChicago$382K
- Dusan StefoskiChicago$294K
- Veronica CiprianiChicago$289K
- Thomas ShoemakerChicago$278K
- Bruce CohenChicago$276K
- Margaret ParkChicago$245K
- Leonard Verhagen MetmanChicago$245K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.